These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22859904)

  • 1. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
    Tamura T; Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2012; 9(6):441-6. PubMed ID: 22859904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
    Sakaeda T; Kadoyama K; Okuno Y
    PLoS One; 2011; 6(12):e28124. PubMed ID: 22205938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
    Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
    Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
    Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
    Kadoyama K; Kuwahara A; Yamamori M; Brown JB; Sakaeda T; Okuno Y
    J Exp Clin Cancer Res; 2011 Oct; 30(1):93. PubMed ID: 21970649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System.
    Tamura T; Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2012; 9(5):322-6. PubMed ID: 22745572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data mining of the public version of the FDA Adverse Event Reporting System.
    Sakaeda T; Tamon A; Kadoyama K; Okuno Y
    Int J Med Sci; 2013; 10(7):796-803. PubMed ID: 23794943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
    Suzuki Y; Suzuki H; Umetsu R; Uranishi H; Abe J; Nishibata Y; Sekiya Y; Miyamura N; Hara H; Tsuchiya T; Kinosada Y; Nakamura M
    Biol Pharm Bull; 2015; 38(5):680-6. PubMed ID: 25947914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system.
    Kadoyama K; Sakaeda T; Tamon A; Okuno Y
    Biol Pharm Bull; 2012; 35(6):967-70. PubMed ID: 22687540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR).
    Moore TJ; Bennett CL
    Semin Thromb Hemost; 2012 Nov; 38(8):905-7. PubMed ID: 23086541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
    Rahman MM; Scalese MJ; Hansen RA
    Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
    Sakaeda T; Kadoyama K; Yabuuchi H; Niijima S; Seki K; Shiraishi Y; Okuno Y
    Int J Med Sci; 2011; 8(4):332-8. PubMed ID: 21611115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database.
    Tanaka J; Koseki T; Sekido K; Kimata M; Ito Y; Yamada S
    J Pharm Pharm Sci; 2023; 26():11263. PubMed ID: 37122387
    [No Abstract]   [Full Text] [Related]  

  • 14. Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.
    Rydberg DM; Holm L; Mejyr S; Loikas D; Schenck-Gustafsson K; von Euler M; Wettermark B; Malmström RE
    Eur J Clin Pharmacol; 2014 Jan; 70(1):117-26. PubMed ID: 24096684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
    Shehab N; Sperling LS; Kegler SR; Budnitz DS
    Arch Intern Med; 2010 Nov; 170(21):1926-33. PubMed ID: 21098354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
    Fahmy AI; Mekkawy MA; Abou-Ali A
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):175-181. PubMed ID: 30738497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
    Buresly K; Eisenberg MJ; Zhang X; Pilote L
    Arch Intern Med; 2005 Apr; 165(7):784-9. PubMed ID: 15824298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
    Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
    J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    Khurram Z; Chou E; Minutello R; Bergman G; Parikh M; Naidu S; Wong SC; Hong MK
    J Invasive Cardiol; 2006 Apr; 18(4):162-4. PubMed ID: 16729401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.